PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Pharmacy, NewYork-Presbyterian Hospital, Columbia University Irving Medical Center, New York, New York, United States of America.\', \'Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, New York, United States of America.\', \'ICAP, Mailman School of Public Health, Columbia University, New York, New York, United States of America.\', \'Department of Health Policy and Management, Mailman School of Public Health, Columbia University, New York, New York, United States of America.\', \'Division of Pulmonary Critical Care, Department of Medicine, Columbia University Irving Medical Center, New York, New York, United States of America.\', \'Division of Rheumatology, Department of Medicine, NewYork-Presbyterian Hospital, Columbia University Irving Medical Center, New York, New York, United States of America.\', \'Division of Infectious Diseases, Department of Pediatrics, Columbia University Irving Medical Center, New York, New York, United States of America.\', \'Department of Medicine, Columbia University Irving Medical Center, New York, New York, United States of America.\', \'Blood and Marrow Transplantation Program, Columbia University Irving Medical Center, New York, New York, United States of America.\', \'Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York, United States of America.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1371/journal.pone.0249349
?:hasPublicationType
?:journal
  • PloS one
is ?:pmid of
?:pmid
?:pmid
  • 33831046
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.164
?:rankingScore_hIndex
  • 241
is ?:relation_isRelatedTo_publication of
?:title
  • What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all